Two new medicines are set to be funded by Pharmac, potentially affecting tens of thousands of patients.
A proposal released this morning would fund Spinraza, a treatment for spinal muscular atrophy, that currently costs up to 390-thousand dollars a year.
The second proposal would fund adrenaline auto-injector pens, such as EpiPens, for those with life-threatening allergies.
Health Minister Andrew Little spoke to Guyon Espiner.
